Aegle Therapeutics ^Private

Aegle Therapeutics is a clinical-stage regenerative medicine company that focuses on developing novel therapeutics using extracellular vesicles (EVs) derived from mesenchymal stem cells. Their proprietary platform technology has the potential to treat a wide range of therapeutic indications, with a current focus on dystrophic epidermolysis bullosa (DEB), a rare pediatric skin blistering disorder. Aegle's EV therapy aims to harness the regenerative, immunomodulatory, and anti-inflammatory properties of MSC-derived EVs to enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis. The company's IND for DEB has been cleared by the FDA, and they expect to enter the clinic by the second half of 2020. Aegle Therapeutics was founded in 2013 and is based in Miami, Florida.